Vyepti

(Eptinezumab)

Vyepti

Drug updated on 11/15/2023

Dosage FormInjection (intravenous: 100 mg/mL)
Drug ClassCalcitonin gene-related peptide antagonists
Ongoing and Completed StudiesClinicalTrials.gov

Indication

  • For the preventive treatment of migraine in adults.

Product Monograph / Prescribing Information

Document TitleYearSource
Vyepti (eptinezumab-jjmr) Prescribing Information.2022Lundbeck Seattle BioPharmaceuticals Inc., Bothell, WA

Systematic Reviews / Meta-Analyses

Document TitleYearSource
Safety and tolerability of monoclonal antibodies targeting the CGRP pathway and gepants in migraine prevention: A systematic review and network meta-analysis.2023Cephalagia
Efficacy and safety of monoclonal antibody against calcitonin gene-related peptide or its receptor for migraine patients with prior preventive treatment failure: a network meta-analysis.2022The Journal of Headache and Pain
Efficacy and safety of eptinezumab as preventive treatment for episodic/chronic migraine: a systematic review and meta-analysis2022Clinical and Experimental Pharmacology and Physiology
Monoclonal antibodies against calcitonin gene-related peptide for migraine prophylaxis: a systematic review of real-world data.2022Cells
Efficacy and safety of anti-calcitonin gene-related peptide monoclonal antibodies for treatment of chronic migraine: a systematic review and network meta-analysis.2021Clinical Neurology and Neurosurgery
Different dosage regimens of eptinezumab for the treatment of migraine: a meta-analysis from randomized controlled trials.2021The Journal of Headache and Pain
Efficacy and safety of monoclonal antibody against calcitonin gene-related peptide or its receptor for migraine: a systematic review and network meta-analysis.2021Frontiers in Pharmacology
Efficacy of calcitonin gene-related peptide (CGRP) receptor blockers in reducing the number of monthly migraine headache days (MHDs): a network meta-analysis of randomized controlled trials.2021Journal of the Neurological Sciences
Safety and tolerability of eptinezumab in patients with migraine: a pooled analysis of 5 clinical trials2021The journal of headache and pain

Clinical Practice Guidelines